Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

36.30 +11.11 (+44.07%)
Delayed Quote Updated: 12:37 PM EDT, Oct 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
4 Analysts Have This to Say About Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira BioSciences Reports Second Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023
From Pacira BioSciences
Via GlobeNewswire
News headline image
Analyst Ratings for Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Looking Into Pacira BioSciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Recap: Pacira BioSciences Q1 Earnings ↗
 
Via Benzinga
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Why Pacira BioSciences Shares Are Trading Lower Today ↗
Pacira BioSciences Inc (NASDAQ: PCRX) reported Q1 sales of $160.3 million compared to $158.0 million a year ago and the  
Via Benzinga
News headline image
Pacira BioSciences Reports First Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
From Pacira BioSciences
Via GlobeNewswire
News headline image
What 6 Analyst Ratings Have To Say About Pacira BioSciences ↗
 
Via Benzinga
News headline image
Analyst Expectations for Pacira BioSciences's Future ↗
 
Via Benzinga
News headline image
Earnings Preview For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner
PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Where Pacira BioSciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
From Pacira BioSciences
Via GlobeNewswire
News headline image
Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Earnings Scheduled For February 28, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions
Multi-year agreement will make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGA 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
From Pacira BioSciences
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 12 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  Tuesday's session saw 16 companies set new 52-week lows. 
Via Benzinga
News headline image
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December 
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.